358 related articles for article (PubMed ID: 28910818)
1. Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma.
Oki E; Okano S; Saeki H; Umemoto Y; Teraishi K; Nakaji Y; Ando K; Zaitsu Y; Yamashita N; Sugiyama M; Nakashima Y; Ohgaki K; Oda Y; Maehara Y
Oncology; 2017; 93(6):387-394. PubMed ID: 28910818
[TBL] [Abstract][Full Text] [Related]
2. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.
Wang L; Zhang Q; Ni S; Tan C; Cai X; Huang D; Sheng W
Cancer Med; 2018 Jun; 7(6):2612-2620. PubMed ID: 29673110
[TBL] [Abstract][Full Text] [Related]
3. Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung.
Hlaing AM; Furusato B; Udo E; Kitamura Y; Souda M; Masutani M; Fukuoka J
Biochem Biophys Res Commun; 2018 Sep; 503(4):2764-2769. PubMed ID: 30100056
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression and tumor infiltrating PD-1+Â lymphocytes associated with outcome in HER2+Â breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.
Yokoyama S; Miyoshi H; Nakashima K; Shimono J; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Ohshima K
Clin Cancer Res; 2016 Sep; 22(18):4727-34. PubMed ID: 27166394
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.
Gao Y; Li S; Xu D; Chen S; Cai Y; Jiang W; Zhang X; Sun J; Wang K; Chang B; Wang F; Hong M
Chin J Cancer; 2017 Jul; 36(1):61. PubMed ID: 28754154
[TBL] [Abstract][Full Text] [Related]
7. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
Han K; Zhang Y
J Cancer Res Ther; 2019; 15(4):914-920. PubMed ID: 31436252
[TBL] [Abstract][Full Text] [Related]
8. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
Martin AM; Nirschl TR; Nirschl CJ; Francica BJ; Kochel CM; van Bokhoven A; Meeker AK; Lucia MS; Anders RA; DeMarzo AM; Drake CG
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):325-32. PubMed ID: 26260996
[TBL] [Abstract][Full Text] [Related]
9. Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma.
Yamashita S; Abe H; Kunita A; Yamashita H; Seto Y; Ushiku T
Histopathology; 2021 Feb; 78(3):381-391. PubMed ID: 32767778
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer.
Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
Cancer Immunol Immunother; 2017 Jul; 66(7):865-876. PubMed ID: 28341875
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study.
Beer A; Taghizadeh H; Schiefer AI; Puhr HC; Karner AK; Jomrich G; Schoppmann SF; Kain R; Preusser M; Ilhan-Mutlu A
Pathol Oncol Res; 2020 Oct; 26(4):2225-2235. PubMed ID: 32372174
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer.
Li Z; Lai Y; Sun L; Zhang X; Liu R; Feng G; Zhou L; Jia L; Huang X; Kang Q; Lin D; Gao J; Shen L
Hum Pathol; 2016 Sep; 55():182-9. PubMed ID: 27260946
[TBL] [Abstract][Full Text] [Related]
13. Programmed cell death ligand-1 expression in gastroenteropancreatic neuroendocrine tumors.
Oktay E; Yalcin GD; Ekmekci S; Kahraman DS; Yalcin A; Degirmenci M; Dirican A; Altin Z; Ozdemir O; Surmeli Z; Diniz G; Ayhan S; Bulut G; Erdogan A; Uslu R
J BUON; 2019; 24(2):779-790. PubMed ID: 31128036
[TBL] [Abstract][Full Text] [Related]
14. Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer.
Wu Y; Zhao T; Jia Z; Cao D; Cao X; Pan Y; Zhao D; Zhang B; Jiang J
J Gastroenterol Hepatol; 2019 Jul; 34(7):1201-1207. PubMed ID: 30353572
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma.
Liu Z; Wen J; Wu C; Hu C; Wang J; Bao Q; Wang H; Wang J; Zhou Q; Wei L; Shen Y; Zhang W
Aging (Albany NY); 2020 Jan; 12(2):1213-1236. PubMed ID: 31981455
[TBL] [Abstract][Full Text] [Related]
16. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1.
Pereira MA; Ramos MFKP; Dias AR; Faraj SF; Ribeiro RRE; de Castria TB; Zilberstein B; Alves VAF; Ribeiro U; de Mello ES
Mol Diagn Ther; 2019 Dec; 23(6):761-771. PubMed ID: 31595457
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.
Sundar R; Qamra A; Tan ALK; Zhang S; Ng CCY; Teh BT; Lee J; Kim KM; Tan P
Gastric Cancer; 2018 Nov; 21(6):1064-1070. PubMed ID: 29915957
[TBL] [Abstract][Full Text] [Related]
18. AKT/mTOR Signal Cascade and Expression of PD-1, PD-L1, and PD-L2 in Gastric Cancer.
Spirina LV; Avgustinovich AV; Afanas'ev SG; Kondakova IV; Volkov MY; Dobrodeev AY; Boronkina AI
Bull Exp Biol Med; 2020 Nov; 170(1):75-78. PubMed ID: 33231797
[TBL] [Abstract][Full Text] [Related]
19. MET is overexpressed in microsatellite instability-high gastric carcinoma.
Sim J; Heo YJ; Bae H; Shin HC; Kim B; Cho J; Kim ST; Lee J; Kang WK; Kim KM
Pathol Res Pract; 2019 Mar; 215(3):433-438. PubMed ID: 30455128
[TBL] [Abstract][Full Text] [Related]
20. Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance.
Yuan J; Zhang J; Zhu Y; Li N; Tian T; Li Y; Li Y; Li Z; Lai Y; Gao J; Shen L
Oncotarget; 2016 Jun; 7(26):39671-39679. PubMed ID: 27191996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
